Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Achillion Pharmaceuticals, Inc. (NQ: ACHN)
7.770 USD  +0.210 (+2.78%)
Official Closing Price  /  Updated: 8:10 PM EDT, May 17, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Achillion Pharmaceuticals, Inc.
 
< Previous 1 2 3 4 5 6 Next >
Achillion Appoints Dr. David Apelian as Chief Medical Officer and Expands Clinical Operations Team
May 15, 2013
from GlobeNewswire News Releases
Achillion to Present at Three Upcoming Investor Conferences
May 09, 2013
from GlobeNewswire News Releases
Achillion Reports First Quarter 2013 Financial Results
May 07, 2013
from GlobeNewswire News Releases
Achillion Presents New Data on ACH-3102 to Treat Hepatitis C at the International Liver Congress
April 23, 2013
from GlobeNewswire News Releases
Achillion Announces Updated Phase 2 Results Including Early Sustained Virologic Response on ACH-3102 Plus Ribavirin in Genotype 1b Treatment-Naive Hepatitis C Patients
April 23, 2013
from GlobeNewswire News Releases
Achillion Initiates Phase 2 Interferon-Free Trial of Sovaprevir and ACH-3102 for Genotype 1 HCV
April 16, 2013
All-Oral Trial to Evaluate the Safety and Efficacy of a 12-Week Regimen of Sovaprevir, ACH-3102 and Ribavirin for Genotype 1 Treatment-Naive HCV Patients Read More
from GlobeNewswire News Releases
Drug Approvals, Breakthrough Treatments and Royalties - Research Report on Celgene Corporation, Onyx Pharmaceuticals, Sarepta Therapeutics, VIVUS and Achillion Pharmaceuticals
March 08, 2013
from PR Newswire
New Programs Designed to Speed Up Approval Process a Key Factor in Biotech Industry's Growth in 2012
March 07, 2013
Five Star Equities Provides Stock Research on Achillion Pharmaceuticals and ISIS Pharmaceuticals Read More
from Marketwired News Releases
Achillion to Present at Two Upcoming Investor Conferences
March 01, 2013
from GlobeNewswire News Releases
Achillion Pharmaceuticals Announces Closing of Public Offering
February 27, 2013
Underwriters Exercise Option to Purchase Additional Shares Read More
from GlobeNewswire News Releases
Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies
February 26, 2013
from PR Newswire
Achillion Pharmaceuticals Announces Pricing of Public Offering of Common Stock
February 21, 2013
from GlobeNewswire News Releases
Achillion Reports 2012 Fourth Quarter and Year-End Financial Results
February 20, 2013
from GlobeNewswire News Releases
Achillion Pharmaceuticals Announces Proposed Public Offering of Common Stock
February 20, 2013
from GlobeNewswire News Releases
Achillion to Report Fourth Quarter and Year End 2012 Financial Results and Host Conference Call on February 20, 2013
February 19, 2013
Conference Call and Live Webcast Will Begin at 5:00 p.m. EST on February 20, 2013 Read More
from GlobeNewswire News Releases
Achillion to Present at the 2013 Leerink Swann Global Healthcare Conference
February 08, 2013
from GlobeNewswire News Releases
U.S. Food and Drug Administration Approved 30% More Drugs in 2012 Than the Year Previous
February 04, 2013
Research Driven Investing Provides Stocks Research on Achillion and Galena Read More
from Marketwired News Releases
Achillion to Present at the Noble Financial Capital Markets' Ninth Annual Equity Conference
January 17, 2013
from GlobeNewswire News Releases
Record Levels of Available Cash and Moderate R&D Development Will See Big Pharma M&A Activity Increase in 2013
January 09, 2013
Five Star Equities Provides Stock Research on Achillion Pharmaceuticals and Dendreon Read More
from Marketwired News Releases
Free Research Reports on ACHN, CHTP, NSM and SQNM Issued by the Bedford Report
January 08, 2013
Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit Read More
from Marketwired News Releases
Achillion Reports Interim Results on ACH-3102
January 07, 2013
from GlobeNewswire News Releases
Achillion to Present at Two Upcoming Investor Conferences
November 30, 2012
from GlobeNewswire News Releases
Achillion to Present at Two Upcoming Investor Conferences
November 13, 2012
from GlobeNewswire News Releases
Direction Change Ahead, What to Expect - Research & Analysis on Achillion Pharmaceuticals, Inc. and Vertex Pharmaceuticals Incorporated
November 13, 2012
from Marketwired News Releases
Higher Rate of FDA New Drug Approvals a Major Factor in Biotech Industry's Success in 2012
November 13, 2012
Five Star Equities Provides Stock Research on Achillion Pharmaceuticals and Sequenom Read More
from Marketwired News Releases
Achillion Provides Update on Clinical HCV Development Programs
November 12, 2012
from GlobeNewswire News Releases
Achillion Pharmaceuticals, Inc. Hosts the HCV Connection Media Briefing at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
November 09, 2012
from PR Newswire
Achillion Reports Third Quarter and Nine Month 2012 Financial Results
November 08, 2012
from GlobeNewswire News Releases
FDA Considering Allowing Developers of Critical Drugs/Treatments to Conduct Smaller, Faster Clinical Trials
October 30, 2012
The Paragon Report Provides Stock Research on Achillion Pharmaceuticals and Halozyme Therapeutics Read More
from Marketwired News Releases
GreeneStone Seeks Amex Listing – New Report Confirms Demand
October 18, 2012
from Business Wire News Releases
< Previous 1 2 3 4 5 6 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here